162 related articles for article (PubMed ID: 8453685)
1. Comparison of the adrenalytic activity of mitotane and a methylated homolog on normal adrenal cortex and adrenal cortical carcinoma.
Schteingart DE; Sinsheimer JE; Counsell RE; Abrams GD; McClellan N; Djanegara T; Hines J; Ruangwises N; Benitez R; Wotring LL
Cancer Chemother Pharmacol; 1993; 31(6):459-66. PubMed ID: 8453685
[TBL] [Abstract][Full Text] [Related]
2. Toxicity, ultrastructural effects, and metabolic studies with 1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane(o,p'-DDD) and its methyl analog in the guinea pig and rat.
Jensen BL; Caldwell MW; French LG; Briggs DG
Toxicol Appl Pharmacol; 1987 Jan; 87(1):1-9. PubMed ID: 3798445
[TBL] [Abstract][Full Text] [Related]
3. Structural requirements for mitotane activity: development of analogs for treatment of adrenal cancer.
Schteingart DE; Sinsheimer JE; Benitez RS; Homan DF; Johnson TD; Counsell RE
Anticancer Res; 2012 Jul; 32(7):2711-20. PubMed ID: 22753730
[TBL] [Abstract][Full Text] [Related]
4. Conventional and novel strategies in the treatment of adrenocortical cancer.
Schteingart DE
Braz J Med Biol Res; 2000 Oct; 33(10):1197-200. PubMed ID: 11004720
[TBL] [Abstract][Full Text] [Related]
5. Bovine adrenal cortex transformations of mitotane [1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane; o,p'-DDD] and its p,p'- and m,p'-isomers.
Cai W; Benitez R; Counsell RE; Djanegara T; Schteingart DE; Sinsheimer JE; Wotring LL
Biochem Pharmacol; 1995 May; 49(10):1483-9. PubMed ID: 7763292
[TBL] [Abstract][Full Text] [Related]
6. The lack of antitumor effects of o,p'DDA excludes its role as an active metabolite of mitotane for adrenocortical carcinoma treatment.
Hescot S; Paci A; Seck A; Slama A; Viengchareun S; Trabado S; Brailly-Tabard S; Al Ghuzlan A; Young J; Baudin E; Lombès M
Horm Cancer; 2014 Oct; 5(5):312-23. PubMed ID: 25026941
[TBL] [Abstract][Full Text] [Related]
7. Treatment of adrenal cortical carcinoma with mitotane: outcome and complications.
Lim MC; Tan YO; Chong PY; Cheah JS
Ann Acad Med Singap; 1990 Jul; 19(4):540-4. PubMed ID: 2171414
[TBL] [Abstract][Full Text] [Related]
8. Mitotane (o,p'-DDD).
Gutierrez ML; Crooke ST
Cancer Treat Rev; 1980 Mar; 7(1):49-55. PubMed ID: 7397707
[No Abstract] [Full Text] [Related]
9. Mitotane treatment of 32 dogs with cortisol-secreting adrenocortical neoplasms.
Kintzer PP; Peterson ME
J Am Vet Med Assoc; 1994 Jul; 205(1):54-61. PubMed ID: 7928549
[TBL] [Abstract][Full Text] [Related]
10. Effects of mitotane on the hypothalamic-pituitary-adrenal axis in patients with adrenocortical carcinoma.
Reimondo G; Puglisi S; Zaggia B; Basile V; Saba L; Perotti P; De Francia S; Volante M; Zatelli MC; Cannavò S; Terzolo M
Eur J Endocrinol; 2017 Oct; 177(4):361-367. PubMed ID: 28780517
[TBL] [Abstract][Full Text] [Related]
11. Assessment of serum-free cortisol levels in patients with adrenocortical carcinoma treated with mitotane: a pilot study.
Alexandraki KI; Kaltsas GA; le Roux CW; Fassnacht M; Ajodha S; Christ-Crain M; Akker SA; Drake WM; Edwards R; Allolio B; Grossman AB
Clin Endocrinol (Oxf); 2010 Mar; 72(3):305-11. PubMed ID: 19473175
[TBL] [Abstract][Full Text] [Related]
12. Comparison of mitotane treatment for adrenal tumor versus pituitary-dependent hyperadrenocorticism in dogs.
Feldman EC; Nelson RW; Feldman MS; Farver TB
J Am Vet Med Assoc; 1992 Jun; 200(11):1642-7. PubMed ID: 1320600
[TBL] [Abstract][Full Text] [Related]
13. ATR-101 disrupts mitochondrial functions in adrenocortical carcinoma cells and in vivo.
Cheng Y; Kerppola RE; Kerppola TK
Endocr Relat Cancer; 2016 Apr; 23(4):1-19. PubMed ID: 26843528
[TBL] [Abstract][Full Text] [Related]
14. Use of urine cortisol:creatinine ratio versus adrenocorticotropic hormone stimulation testing for monitoring mitotane treatment of pituitary-dependent hyperadrenocorticism in dogs.
Angles JM; Feldman EC; Nelson RW; Feldman MS
J Am Vet Med Assoc; 1997 Oct; 211(8):1002-4. PubMed ID: 9343543
[TBL] [Abstract][Full Text] [Related]
15. Effect of bursal anti-steroidogenic peptide (BASP) on cortisol biosynthesis in ACTH-stimulated canine adrenocortical carcinoma cells in vitro.
Byrd JA; Dean CE; Fossum TW; Hargis BM
Vet Immunol Immunopathol; 1995 Jul; 47(1-2):35-42. PubMed ID: 8533298
[TBL] [Abstract][Full Text] [Related]
16. Mitotane Inhibits Sterol-O-Acyl Transferase 1 Triggering Lipid-Mediated Endoplasmic Reticulum Stress and Apoptosis in Adrenocortical Carcinoma Cells.
Sbiera S; Leich E; Liebisch G; Sbiera I; Schirbel A; Wiemer L; Matysik S; Eckhardt C; Gardill F; Gehl A; Kendl S; Weigand I; Bala M; Ronchi CL; Deutschbein T; Schmitz G; Rosenwald A; Allolio B; Fassnacht M; Kroiss M
Endocrinology; 2015 Nov; 156(11):3895-908. PubMed ID: 26305886
[TBL] [Abstract][Full Text] [Related]
17. [Activity of glutathione reductase in the adrenal glands and the liver of dogs after administration O,P-DDD, perthane and ACTH].
Komissarenko VP; Chelnakova IS; Mikosha AS
Probl Endokrinol (Mosk); 1978; 24(1):95-8. PubMed ID: 204922
[TBL] [Abstract][Full Text] [Related]
18. Immediate versus modified release hydrocortisone in mitotane-treated patients with adrenocortical cancer.
Weigel M; Hahner S; Sherlock M; Agha A; Behan LA; Stewart PM; Arlt W; Beier D; Frey K; Zopf K; Quinkler M
Clin Endocrinol (Oxf); 2017 Apr; 86(4):499-505. PubMed ID: 28063163
[TBL] [Abstract][Full Text] [Related]
19. Mitotane exhibits dual effects on steroidogenic enzymes gene transcription under basal and cAMP-stimulating microenvironments in NCI-H295 cells.
Lin CW; Chang YH; Pu HF
Toxicology; 2012 Aug; 298(1-3):14-23. PubMed ID: 22546480
[TBL] [Abstract][Full Text] [Related]
20. Effects of mitotane on gene expression in the adrenocortical cell line NCI-H295R: a microarray study.
Zsippai A; Szabó DR; Tömböl Z; Szabó PM; Eder K; Pállinger E; Gaillard RC; Patócs A; Tóth S; Falus A; Rácz K; Igaz P
Pharmacogenomics; 2012 Sep; 13(12):1351-61. PubMed ID: 22966885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
